Targeted therapies: Evolve and... surrender!

Nature Reviews Clinical Oncology

Volumn 8, Issue 6, 2011, Pages 315-

  Villanueva, M Teresa ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; SCATTER FACTOR RECEPTOR;

EGFR GENE; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MET GENE; MOLECULARLY TARGETED THERAPY; NOTE; PHENOTYPE; PIK3CA GENE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR BIOPSY;

EID: 79958040405     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.60     Document Type: Note

References (1)

1. Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Trans. Med. 3, 75ra26 (2011)